Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Johnson and Johnson
McKinsey
Mallinckrodt
Dow

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PHENTERMINE RESIN 30

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Phentermine Resin 30

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000506 Cardiovascular System in Obesity: Effect of Treatment Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1983-05-01 To determine the long-term efficacy of the combination therapy of phentermine and fenfluramine in conjunction with diet, exercise, and behavior modification in the treatment of simple, moderate obesity.
NCT00402077 A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 2006-11-01 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
NCT00518466 Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults Completed VIVUS, Inc. Phase 1 2007-07-01 The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.
NCT00563368 A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed Medpace, Inc. Phase 3 2007-12-01 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00563368 A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed VIVUS, Inc. Phase 3 2007-12-01 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00600067 A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults Completed Sentrx Phase 2 2008-01-01 The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Phentermine Resin 30

Condition Name

Condition Name for Phentermine Resin 30
Intervention Trials
Obesity 18
Drug Abuse 3
Binge Eating Disorder 2
Bariatric Surgery 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Phentermine Resin 30
Intervention Trials
Obesity 8
Overweight 7
Weight Loss 4
Obesity, Morbid 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Phentermine Resin 30

Trials by Country

Trials by Country for Phentermine Resin 30
Location Trials
United States 68
Mexico 2
Canada 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Phentermine Resin 30
Location Trials
California 9
Florida 5
Texas 5
Virginia 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Phentermine Resin 30

Clinical Trial Phase

Clinical Trial Phase for Phentermine Resin 30
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2 10
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Phentermine Resin 30
Clinical Trial Phase Trials
Completed 16
Recruiting 7
Withdrawn 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Phentermine Resin 30

Sponsor Name

Sponsor Name for Phentermine Resin 30
Sponsor Trials
VIVUS, Inc. 7
AstraZeneca 4
Synteract, Inc. 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Phentermine Resin 30
Sponsor Trials
Other 25
Industry 21
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
Express Scripts
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.